672 related articles for article (PubMed ID: 28906574)
1. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS
Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574
[TBL] [Abstract][Full Text] [Related]
2. A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma.
Fabi SG; Friedmann DP; Niwa Massaki AB; Goldman MP
Lasers Surg Med; 2014 Sep; 46(7):531-7. PubMed ID: 24895301
[TBL] [Abstract][Full Text] [Related]
3. Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
Manuskiatti W; Yan C; Gulfan MCB; Techapichetvanich T; Wanitphakdeedecha R
Lasers Surg Med; 2022 Dec; 54(10):1245-1250. PubMed ID: 36345697
[TBL] [Abstract][Full Text] [Related]
4. Effects of a fractional picosecond 1,064 nm laser for the treatment of dermal and mixed type melasma.
Chalermchai T; Rummaneethorn P
J Cosmet Laser Ther; 2018 Jun; 20(3):134-139. PubMed ID: 29020467
[TBL] [Abstract][Full Text] [Related]
5. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.
Wattanakrai P; Mornchan R; Eimpunth S
Dermatol Surg; 2010; 36(1):76-87. PubMed ID: 20298254
[TBL] [Abstract][Full Text] [Related]
6. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
[TBL] [Abstract][Full Text] [Related]
7. Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma.
Laothaworn V; Juntongjin P
J Cosmet Laser Ther; 2018 Oct; 20(6):320-325. PubMed ID: 29461121
[No Abstract] [Full Text] [Related]
8. A randomized, observer-blinded, comparison of combined 1064-nm Q-switched neodymium-doped yttrium-aluminium-garnet laser plus 30% glycolic acid peel vs. laser monotherapy to treat melasma.
Park KY; Kim DH; Kim HK; Li K; Seo SJ; Hong CK
Clin Exp Dermatol; 2011 Dec; 36(8):864-70. PubMed ID: 21973194
[TBL] [Abstract][Full Text] [Related]
9. Low-power fractional CO₂ laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study.
Jalaly NY; Valizadeh N; Barikbin B; Yousefi M
Am J Clin Dermatol; 2014 Aug; 15(4):357-63. PubMed ID: 24858737
[TBL] [Abstract][Full Text] [Related]
10. A split face study to document the safety and efficacy of clearance of melasma with a 5 ns q switched Nd YAG laser versus a 50 ns q switched Nd YAG laser.
Alsaad SM; Ross EV; Mishra V; Miller L
Lasers Surg Med; 2014 Dec; 46(10):736-40. PubMed ID: 25411141
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 755-nm picosecond alexandrite laser versus 1064-nm Q-switched Nd:YAG laser for melasma: A randomized, split-face controlled, 2-year follow-up study.
Zhou Y; Li Y; Hamblin MR; Wen X
Lasers Surg Med; 2024 Mar; 56(3):263-269. PubMed ID: 38282099
[TBL] [Abstract][Full Text] [Related]
12. Treatment of melasma in men with low-fluence Q-switched neodymium-doped yttrium-aluminum-garnet laser versus combined laser and glycolic acid peeling.
Vachiramon V; Sahawatwong S; Sirithanabadeekul P
Dermatol Surg; 2015 Apr; 41(4):457-65. PubMed ID: 25760554
[TBL] [Abstract][Full Text] [Related]
13. A split-face, investigator-blinded comparative study on the efficacy and safety of Q-switched Nd:YAG laser plus microneedling with vitamin C versus Q-switched Nd:YAG laser for the treatment of recalcitrant melasma.
Ustuner P; Balevi A; Ozdemir M
J Cosmet Laser Ther; 2017 Nov; 19(7):383-390. PubMed ID: 28657378
[TBL] [Abstract][Full Text] [Related]
14. Treatment of melasma with mixed parameters of 1,064-nm Q-switched Nd:YAG laser toning and an enhanced effect of ultrasonic application of vitamin C: a split-face study.
Lee MC; Chang CS; Huang YL; Chang SL; Chang CH; Lin YF; Hu S
Lasers Med Sci; 2015 Jan; 30(1):159-63. PubMed ID: 25073866
[TBL] [Abstract][Full Text] [Related]
15. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.
Jeong SY; Shin JB; Yeo UC; Kim WS; Kim IH
Dermatol Surg; 2010 Jun; 36(6):909-18. PubMed ID: 20384749
[TBL] [Abstract][Full Text] [Related]
16. Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma.
Vachiramon V; Sirithanabadeekul P; Sahawatwong S
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1339-46. PubMed ID: 25413592
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of picosecond Nd:YAG laser (1,064 nm), picosecond alexandrite laser (755 nm) and 2% hydroquinone cream in the treatment of melasma: A randomized, controlled, assessor-blinded trial.
Liang S; Shang S; Zhang W; Tan A; Zhou B; Mei X; Li L
Front Med (Lausanne); 2023; 10():1132823. PubMed ID: 37056729
[TBL] [Abstract][Full Text] [Related]
18. A prospective, split-face study comparing 1,064-nm picosecond Nd:YAG laser toning with 1,064-nm Q-switched Nd:YAG laser toning in the treatment of melasma.
Hong JK; Shin SH; Park SJ; Seo SJ; Park KY
J Dermatolog Treat; 2022 Aug; 33(5):2547-2553. PubMed ID: 35067157
[TBL] [Abstract][Full Text] [Related]
19. Long-term results in low-fluence 1064-nm Q-Switched Nd:YAG laser for melasma: Is it effective?
Gokalp H; Akkaya AD; Oram Y
J Cosmet Dermatol; 2016 Dec; 15(4):420-426. PubMed ID: 27349828
[TBL] [Abstract][Full Text] [Related]
20. 755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial.
Lai D; Cheng S; Zhou S; Hao J; Chen H; Jia K; Liu H; Cui Y
Lasers Med Sci; 2024 Apr; 39(1):113. PubMed ID: 38656631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
